New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, investigators assessed the efficacy and safety of RYBREVANT® in patients (n=114) with NSCLC and EGFR exon 20 insertion mutations, who had progressed on prior platinum-based chemotherapy, and were treated at the approved Phase 2 dose of 1050 mg (1400 mg for a patient weight of at least 80 kg).1 The primary endpoint was overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1* (RECIST v1.1).1 Additional endpoints included duration of response (DOR), clinical benefit rate, progression-free survival (PFS) and overall survival (OS).1After a median follow-up of 19.2 months, the median OS with RYBREVANT® treatment was 23 months (95 percent Confidence Interval [CI], 18.5–29.5) with a two-year OS rate of 47 percent.1 The investigator-assessed ORR was 37 percent (95 percent CI, 28–46) with a median DOR of 12.5 months (95 percent CI, 6...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Adenocarcinoma | Alcoholism | Alimta | Allergy & Immunology | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Denmark Health | Dermatitis | Dermatology | Food and Drug Administration (FDA) | Genetics | Health Management | Heart | Hospitals | Hypertension | Immunotherapy | Infectious Diseases | Interstitial Lung Disease | Laboratory Medicine | Learning | Legislation | Lung Cancer | Netherlands Health | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Opthalmology | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Politics | Potassium | Pregnancy | Pulmonary Hypertension | Science | Skin | Skin Cancer | Sodium | Spain Health | Squamous Cell Carcinoma | Study | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations